(NASDAQ: OCS) Oculis Holding Ag's forecast annual revenue growth rate of 319.67% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Oculis Holding Ag's revenue in 2026 is $1,537,179.On average, 12 Wall Street analysts forecast OCS's revenue for 2026 to be $393,540,381, with the lowest OCS revenue forecast at $45,459,799, and the highest OCS revenue forecast at $2,496,230,056. On average, 11 Wall Street analysts forecast OCS's revenue for 2027 to be $2,281,455,698, with the lowest OCS revenue forecast at $159,109,298, and the highest OCS revenue forecast at $6,319,144,053.
In 2028, OCS is forecast to generate $7,189,490,468 in revenue, with the lowest revenue forecast at $1,022,845,486 and the highest revenue forecast at $18,724,334,719.